~~<i id='47B06C1BDC'><strike id='47B06C1BDC'><tt id='47B06C1BDC'><pre id='47B06C1BDC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

author：focus 2025-09-30 18:59:13 - browse：96492

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Prior authorization will have to move faster under new Biden rule

leisure time

explore

hotspot

focus

leisure time

hotspot

MikeReddyforSTATSincethepandemic,patientshavebecomeincreasinglycomfortablewithgettingtheirmedication

WSS

Paxlovid study fails to answer questions over benefit for broader groups

Parkinson’s finding may lead to tests and, someday, treatments

Francis Collins on trust in science and how Covid communications failed

Do masks work? RCTs can't tell us

Independent physicians launch a new lobbying group

Death of patient in Alzheimer’s trial raises question of possible risks

explore

explore

leisure time

Apple is now the first public company to be valued at $3 trillion

Weight bias in eating disorder treatment complicated by new weight loss drugs

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Merck, J&J, and long Covid

Supreme Court strikes down use of affirmative action

The battle over the Brookhaven Landfill on Long Island

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Weight bias in eating disorder treatment complicated by new weight loss drugs

Medicare details structure of new drug price negotiation program

CDC concerned about possible undetected monkeypox spread in U.K.

explore

AI generated plenty of interest at JPM but not a lot of trust

Eli Lilly, Pfizer, and others want in on the online prescription market

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Weight bias in eating disorder treatment complicated by new weight loss drugs

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

hotspot

focus

leisure time

hotspot